Genexine Co., Ltd.

Genexine Co., Ltd. operates as a biotechnology company focused on the development and commercialization of innovative immunotherapeutic drugs and technologies. With a strategic emphasis on treating cancer and infectious diseases, Genexine leverages its proprietary hybrid Fc (HyFc) technology platform to enhance the efficacy and longevity of biologic drugs. This South Korean company plays a pivotal role in the biopharmaceutical industry, contributing to both its domestic and global markets by advancing groundbreaking therapies that aim to meet unmet medical needs. Genexine's robust pipeline includes drug candidates for various immune-related conditions and cancer treatments, positioning it as a key player in the evolving landscape of biotech-driven healthcare solutions. The company’s commitment to innovation and collaboration with international research organizations underscores its strategic importance in the quest for next-generation therapies."}